Zucker Diabetic Fatty (ZDF) Rat Diet Update
August 16, 2010 - The obese male Zucker Diabetic Fatty (ZDF) rat plays a pivotal role in studying the cascade of physiologic events associated with the onset and treatment of type 2 diabetes (T2D). The female ZDF can also be used as a model for T2D, but unlike the male, the female requires dietary modification to induce the diabetic state.
Historically, females fed Research Diets (RD) C13004 diet starting at six weeks of age consistently developed diabetes by 12 weeks of age. The C13004 diet consists of a grain base supplemented with added fat. During the fall of 2007, several research groups reported to Charles River that female ZDF rats fed C13004 did not reliably develop diabetes.
Subsequently, Charles River learned that certain nutritional components of RD C13004 had been modified. After first ruling out environmental and genetic factors as possible causes of the loss of the diabetic phenotype, Charles River experimentally evaluated the RD C13004 diet and confirmed that it no longer reliably produced diabetes in the obese female. In order to determine an effective diet, Charles River performed a series of studies that indicated that the semi-purified diet RD 12468 reliably produced a diabetic phenotype, indicated by hyperglycemia and insulinopenia, in the female ZDF rat.
Charles River recommends that investigators consider utilizing RD 12468 to reliably induce a diabetic phenotype in the female ZDF rat. Alternatively, Charles River can provide preconditioned female ZDF rats fed RD 12468 upon request.
To read the full technical sheet on this study, please click here.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
Clinical pathology data can assist you in selecting the most appropriate model for your study and can provide important information on the physiology and health of your research animals.
We are now the exclusive distributor of the TARGATT™ mouse. The TARGATT mouse is a transgenic mouse designed to produce animal models with investigator designed exogenous DNA sequences knocked-in to a specific site.
Jun 10–Jun 13
Visit us in booth #091 to learn more about our recent innovations including expanded diagnostic capabilities, a new online portal connecting clients with their colonies and a deep-rooted commitment to humane care.
May 20–May 22
Please visit Charles River tabletop #611 to discuss our full portfolio of products and services, including our Preclinical Services, as well as our Biopharmaceutical Services, which deliver client-focused solutions for the specific testing and manufacturing requirements of your biologic.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.